Algernon Pharmaceuticals to provide interim data from Ifenprodil Phase 2b/3 human study
Algernon Pharmaceuticals (CSE: AGN-OTCQB: AGNPF) CEO Christopher Moreau discusses news with Steve Darling from Proactive that the company will be sharing interim data from its multi-national Ifenprodil Phase 2b/3 COVID-19 human study. Mr. Moreau explains to Proactive that the interim data will consist of 75 patients on day 15 of the study and will be presented in a descriptive statistics format. Algernon Pharmaceuticals is projecting the data readout will be in the first week of December 2020. …
Proactive Investor – Interview with CEO Christopher Moreau regarding the approval from the Data and Safety Monitoring Board to continue the study
Algernon Pharmaceuticals (CSE: AGN-OTCQB: AGNPF) CEO Christopher Moreau joined Steve Darling from Proactive to bring news that the company has heard from the external Data and Safety Monitoring Board which has once again unanimously approved the continuation of the Company’s multinational Phase 2b/3 human study of Ifenprodil for the treatment of COVID-19. Moreau talks about moving forward his thoughts about Ifenprodil compared to others. …
Facebook Live – Algernon Pharmaceuticals Update with CEO Christopher Moreau
Algernon Pharmaceuticals Update & Recap with CEO Christopher Moreau Interview with Algernon Pharmaceuticals CEO Christopher Moreau and Cyndi Edwards of PR Media Now on Facebook Live October 28, 2020 …
Ifenprodil COVID-19 Updates with Algernon CEO Christopher Moreau
Christopher J. Moreau, CEO, Algernon Pharmaceuticals live on Facebook to update investors on our multinational Phase 2b/3 trial of Ifenprodil. The event was held on October 2nd at 2 PM ET. …
The Science behind Ifenprodil and COVID -19
Dr. Mark Williams, Chief Science Officer of Algernon Pharmaceuticals Inc. (CSE: AGN | FRANKFURT: AGW |OTCQB: AGNPF) speaks about two basic lines of evidence that suggest Ifenprodil should be active in treating COVID-19 patients. Algernon is a drug re-purposing company that investigates safe, already approved drugs for new disease applications, moving them efficiently and safely into new human trials, developing new formulations and seeking new regulatory approvals in global markets. …
Algernon Pharmaceuticals provides update on Phase 2B/3 study as they enroll 50th patient
Algernon Pharmaceuticals provides update on Phase 2B/3 study as they enroll 50th patient Algernon Pharmaceutical (CSE: AGN-OTCQB: AGNPF) CEO Christopher Moreau joined Steve Darling from Proactive Vancouver with news the company has now enrolled a third of their patients in the Phase 2B/3 study of their repurposed drug Ifenprodil. Moreau discusses hitting that mark and also discusses the parameters of that study and whether they plan on releasing early data. …
Algernon Pharmaceuticals has big upside, says Mackie Research
Algernon Pharmaceuticals has big upside, says Mackie Research Mackie Research launched coverage on Wednesday on drug developer Algernon Pharmaceuticals (Algernon Pharmaceuticals Stock Quote, Chart, News CSE:AGN) with a “Speculative Buy” rating, with analyst André Uddin saying the stock has a number of catalysts over the next few quarters. Vancouver-based Algernon is focused on repurposing for new indications in the US and European markets small molecule drugs already approved and genericized outside of those districts. Currently, Algernon has four repurposed drug candidates in its pipeline for indications including COVID-19, idiopathic pulmonary fibrosis (IPF), chronic cough, CKD, NASH and inflammatory bowel …
‘An effective treatment to reduce the severity and duration of a COVID infection’ – The Mercury
‘An effective treatment to reduce the severity and duration of a COVID infection’ – The Mercury UTD study identifies multi-purpose use for drug Ifenprodil A pharmaceutical company used a research study from UTD for affirming its potential treatment for COVID-19 recovery. COVID-19 causes inflammation in the lungs. Co-author of the research study in question — BBS professor Theodore Price — said this inflammatory response is initially caused by the immune system but can later be exacerbated by the nervous system. Neurogenic inflammation, which occurs when the nervous system and immune system start to interact, is driven by …
Pharmaceutical Firm Doses First Patient in Phase 2 IPF and Chronic Cough Trial
Pharmaceutical Firm Doses First Patient in Phase 2 IPF and Chronic Cough Trial Algernon Pharmaceuticals reported that the first patient has been dosed in the Phase 2 human study of Ifenprodil for treatment of idiopathic pulmonary fibrosis and chronic cough. In a news release, Algernon Pharmaceuticals Inc. (AGN:CSE; AGNPF:OTCQB; AGW:FSE) announced that “the first patient has been dosed in its Phase 2 idiopathic pulmonary fibrosis (IPF) and chronic cough clinical study of its re-purposed drug NP-120 (Ifenprodil).” The firm advised that this patient was enrolled and dosed at New Zealand’s Waikato Hospital. Algernon Pharmaceuticals noted that the objective of …
Miami Herald – A pill that may lessen COVID-related lung damage. Miami will be the first in U.S. to test it.
A pill that may lessen COVID-related lung damage. Miami will be first in U.S. to test it. A Miami hospital will be the first in the country to test a possible COVID-19 treatment on humans this August. The research center at Westchester General Hospital in Coral Terrace is on its way to enroll patients to test Ifenprodil, a pill developed in the 1970s to treat blood circulation disorders that may alleviate some COVID-19 side-effects in the lungs. The drug, which was tested on a coronavirus patient overseas for the first time Wednesday, may reduce the severity and duration of …
About Us
Latest News
